Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GRAVITAS Fails To Show Clinical Value Of Platelet Function Testing For Plavix

This article was originally published in The Pink Sheet Daily

Executive Summary

Study results don't prove clinical benefit for point-of-care testing, but trial may not have been sufficiently powered to show a difference.

You may also be interested in...



Building Data Infrastructure For PCORI Research Should Start Now, NIH’s Collins Says

NIH Director Collins, a member of the Patient-Centered Outcomes Research Institute board of governors, offered his vision of a data infrastructure that would enable PCORI to maximize its research capabilities while minimizing costs of conducting research. At the same PCORI-sponsored workshop, Institute Executive Director Joe Selby described the main characteristics a national data infrastructure should offer.

Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations

The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.

Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations

The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel